A5088394227- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- 3D Printing in Biomedical Research
- Cancer Immunotherapy and Biomarkers
- Liver physiology and pathology
- Liver Disease and Transplantation
- Cancer, Lipids, and Metabolism
- Cancer Cells and Metastasis
- Ferroptosis and cancer prognosis
- Hepatitis B Virus Studies
- Diet and metabolism studies
- Dietary Effects on Health
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Neuroendocrine Tumor Research Advances
- Gut microbiota and health
- Genetic and Kidney Cyst Diseases
- Gallbladder and Bile Duct Disorders
- Cancer-related molecular mechanisms research
- Endoplasmic Reticulum Stress and Disease
- Cancer, Hypoxia, and Metabolism
- Organ Transplantation Techniques and Outcomes
Peking Union Medical College Hospital
2016-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
Lanzhou University
2025
Renji Hospital
2023
Wuxi Fourth People's Hospital
2023
Ruijin Hospital
2022
Shanghai Jiao Tong University
2022
Fudan University
2022
Zhongshan Hospital
2022
Academy of Medical Sciences
2015-2021
<b><i>Background:</i></b> Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and second leading cause of tumor-related death, thereby posing a significant threat to life health Chinese people. <b><i>Summary:</i></b> Since publication <i>Guidelines for Diagnosis Treatment Liver Cancer (2017 Edition)</i> 2018, additional high-quality evidence has emerged with relevance...
<h3>Background and aims</h3> Golgi protein 73 (GP73) as a potential serum marker for hepatocellular carcinoma (HCC) has not been validated in large cohort studies. Furthermore, its significance the assessment of tumour recurrence after HCC resection remains unknown. The aim this study was to determine value GP73 diagnosis HCC. <h3>Methods</h3> Serum alpha-fetoprotein (AFP) were compared total 4217 human subjects multicentre study, including 1690 healthy adults, 337 hepatitis B virus (HBV)...
Primary liver cancer, of which around 75-85% is hepatocellular carcinoma in China, the fourth most common malignancy and second leading cause tumor-related death, thereby posing a significant threat to life health Chinese people.Since publication Guidelines for Diagnosis Treatment Liver Cancer China June 2017, were updated by National Health Commission December 2019, additional high-quality evidence has emerged from researchers worldwide regarding diagnosis, staging, treatment that requires...
Time-restricted feeding (TRF) improves metabolic health. Both early TRF (eTRF, food intake restricted to the part of day) and mid-day (mTRF, middle have been shown benefits. However, two regimens yet be thoroughly compared. We conducted a five-week randomized trial compare effects in healthy individuals without obesity (ChiCTR2000029797). The has completed. Ninety participants were eTRF (n=30), mTRF or control groups (n=30) using computer-based random-number generator. Eighty-two completed...
Objective Shortage of organ donors, a critical challenge for treatment end-stage failure, has motivated the development alternative strategies to generate organs in vitro. Here, we aim describe hepatorganoids, which is liver tissue model generated by three-dimensional (3D) bioprinting HepaRG cells and investigate its functions vitro vivo. Design 3D bioprinted hepatorganoids (3DP-HOs) were constructed using bioink, according specific printing procedures. Liver 3DP-HOs detected after 7 days...
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis clinical staging of hepatocellular carcinoma (HCC). We have published first version guideline 2016 revised 2018. Over past several years, many new evidences for treatment PVTT become available, especially advent targeted drugs immune checkpoint inhibitors which further improved PVTT. So, Chinese Association Liver Cancer Medical Doctor 2018 to adapt development treatment. Future strategies HCC with...
Combining lenvatinib with a programmed cell death protein-1 (PD-1) inhibitor has been explored for the treatment of un-resectable hepatocellular carcinoma (uHCC). This study aimed to investigate real-world efficacy and prognostic factors survival associated plus PD-1 in large cohort Asian uHCC patients even global LEAP-002 failed achieve primary endpoints.
The dismal prognosis of hepatocellular carcinoma (HCC) is closely associated with characteristics the tumour microenvironment (TME). Recent studies have confirmed presence and potential influence microbiome in TME on cancer progression. Elucidating relationship between microbes could provide valuable insights into novel diagnostic markers therapeutic strategies for HCC thus warrants a closer investigation role intratumoural TME.
Background: The global burden of metabolic diseases is increasing, but estimates their impact on primary liver cancer are uncertain. We aimed to assess the attributable risk factors, including high body mass index (BMI) and fasting plasma glucose (FPG) levels, between 1990 2021. Methods: total number age-standardized rates deaths disability-adjusted life years (DALYs) from each factor were extracted Global Burden Disease Study 1990-2021. trends across regions countries by sociodemographic...
Background: A therapeutic strategy involving combined treatment with lenvatinib plus pembrolizumab (LEP) has demonstrated a relatively high antitumor response in several solid tumors; however, the efficacy and safety of LEP patients refractory bile tract carcinoma (BTC) remains unknown. Methods: This is single-arm study for preliminary assessment tolerability who experienced progression from prior systemic treatments. Pre-treatment tumor tissues were collected to retrospectively evaluate...
Abstract The aberrant expression of long noncoding RNAs (lncRNAs) has drawn increasing attention in the field hepatocellular carcinoma (HCC) biology. In present study, we obtained profiles lncRNAs, microRNAs (miRNAs), and messenger (mRNAs) 371 HCC tissues 50 normal from Cancer Genome Atlas (TCGA) identified hepatocarcinogenesis‐specific differentially expressed genes (DEGs, log fold change ≥ 2, FDR < 0.01), including 753 97 miRNAs, 1,535 mRNAs. Because specific functions lncRNAs are...
Detection of circulating cell-free DNA (cfDNA) has potential clinical value for assessing tumor biology in patients with hepatocellular carcinoma (HCC), yet many traditional assays lack robustness. This study was the first to apply a high-throughput sequencing platform detect tumor-associated mutations HCC from tumor-derived (ctDNA) and evaluate utility feasibility this approach.Using MiSeq™ system, plasma matched samples were analyzed hotspot TERT, CTNNB1, TP53 genes that had been verified...
The existing in vitro models for antitumor drug screening have great limitations. Many compounds that inhibit 2D cultured cells do not exhibit the same pharmacological effects vivo, thereby wasting human and material resources as well time during development. Therefore, developing new is critical. 3D bioprinting technology has greater advantages constructing tissue compared with sandwich culture organoid construction. Here, we used to construct a model HepG2 (3DP-HepG2). biological...
Towards the development of in vivo-mimicking tumor model for extensive study tumorigenesis and establishment personalized therapy, patient-derived primary cells were employed this work three-dimensional (3D) bioprinting. Intrahepatic cholangiocarcinoma isolated from patient bioprinted using a composite hydrogel system gelatin-alginate-MatrigelTM into pre-designed grid architecture. ICC observed to process colony forming ability with high survival rate active proliferation. Expression levels...